The relative role of peripheral blood and bone marrow for monitoring molecular evidence of disease in follicular lymphoma by quantitative real-time polymerase chain reaction.
Peripheral blood (PB) and bone marrow (BM) are used interchangeably for t(14;18) (IgH/BCL-2) molecular monitoring in follicular lymphoma (FL) and detection of rearrangement after treatment has been correlated to increased risk of relapse. To determine the relative value of each tissue, MBR t(14;18) was quantified by real-time polymerase chain reaction in 52 simultaneous paired PB and BM samples from 38 FL patients. In total, 79% of sample pairs taken in remission (n = 19) or when no morphological disease was evident in the BM (n = 29) had t(14;18) copy number within one log difference and the median difference was small. These findings suggest that, in remission, PB may be adequately monitored. In general, however, higher copy number was detected in BM than in the corresponding PB sample.
Summers
Karin E
KE
Cancer Research UK--Medical Oncology Unit, Department of Medical Oncology, Charterhouse Square, London EC1M 6BQ, UK.
Davies
Andrew J
AJ
Matthews
Janet
J
Jenner
Michael J
MJ
Cornelius
Victoria
V
Amess
John A
JA
Norton
Andrew J
AJ
Rohatiner
Ama Z S
AZ
Fitzgibbon
Jude
J
Lister
T Andrew
TA
Goff
Lindsey K
LK
D001769:Blood; D001853:Bone Marrow / Q000473:pathology*; D019457:Chromosome Breakage; D002883:Chromosomes, Human, Pair 14 / Q000235:genetics*; D002887:Chromosomes, Human, Pair 18 / Q000235:genetics*; D015321:Gene Rearrangement; D006801:Humans; D008224:Lymphoma, Follicular / Q000235:genetics* / Q000473:pathology; D018365:Neoplasm, Residual; D016133:Polymerase Chain Reaction / Q000379:methods*